Since becoming aware of disruptions in CADD-MS3 (MS3) access earlier this year, the Pulmonary Hypertension Association (PHA) has been meeting with stakeholders and advocating on behalf of health care professionals and patients. To date, PHA has met with ICU Medical (device manufacturer); United Therapeutics Corporation (Remodulin); Liquidia (generic treprostinil); and Accredo Specialty Pharmacy. The
With great sadness, the Pulmonary Hypertension Association announces the death of Rino Aldrighetti, who led PHA for nearly two decades. Rino, who died May 30, was the first PHA employee, hired in 1999 as part-time executive director. He soon became full-time and later was promoted to president and CEO. He retired in 2016.
Pregnancy is considered high risk for people with pulmonary hypertension because their heart and lungs can’t easily adjust to the demands of pregnancy and childbirth.